Skip to main content
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. — Investor Relations & Filings

Ticker · HOWL ISIN · US95075A1079 US Manufacturing
Filings indexed 367 across all filing types
Latest filing 2022-03-24 Annual Report
Country US United States of America
Listing US HOWL

About Werewolf Therapeutics, Inc.

https://werewolftx.com/

Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2021
2022-03-24 English
8-K
Earnings Release Classification · 90% confidence The document is a Form 8-K filed with the SEC, dated March 24, 2022, by Werewolf Therapeutics, Inc. It announces the issuance of a press release with financial results for the quarter ended December 31, 2021. The document explicitly states that the press release is being furnished as an exhibit and that the information is not deemed "filed" for certain regulatory purposes. The document length is 3788 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than containing the earnings data itself. According to the rules, such a document that announces or furnishes a press release of financial results but does not contain the financial results itself should be classified as an Earnings Release (ER) if it contains key highlights or as Regulatory Filings (RNS) if it is just an announcement. However, since the document includes the press release as an exhibit and announces financial results for a quarter, it aligns with the characteristics of an Earnings Release (ER).
2022-03-24 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-11 English
FORM 4 SUBMISSION
Director's Dealing
2022-01-19 English
FORM 4 SUBMISSION
Director's Dealing
2022-01-19 English
FORM 4 SUBMISSION
Director's Dealing
2022-01-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.